Download PDF
Aktuelle Neurologie 2005; 32(2): 77-85
DOI: 10.1055/s-2004-834641
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Medikamentöse Therapie depressiver Störungen beim Morbus Parkinson

Treatment of Depressive Disorders in Parkinson's DiseaseJ.  Reiff1 , K.  Witt2 , G.  Deuschl2
  • 1Klinik für Psychiatrie und Psychotherapie, Christian-Albrechts-Universität Kiel
  • 2Klinik für Neurologie, Christian-Albrechts-Universität Kiel
Further Information

Publication History

Publication Date:
02 March 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Depressive Störungen bei Morbus Parkinson werden zu selten diagnostiziert und therapiert, obwohl sie bei 40 % aller Patienten auftreten. An ihrer Pathogenese sind organische und psychologische Faktoren beteiligt. Sie beeinträchtigen als einer von drei wichtigen Faktoren die Lebensqualität. Die Diagnostik kann mit Hilfe von Fremd- und Selbstbeurteilungsskalen vereinfacht werden. Eine Optimierung der dopamimetischen Medikation reicht bei den meisten Patienten nicht aus, sodass die Gabe eines Antidepressivums erforderlich wird. Die derzeitige Studienlage zur Wirksamkeit und Verträglichkeit der Antidepressivatherapie bei Morbus Parkinson erlaubt keine evidenzbasierten Therapieempfehlungen. Obwohl die neueren Antidepressiva wie die selektiven Serotoninwiederaufnahmehemmer im Vergleich zu den älteren Antidepressiva wie den trizyklischen Antidepressiva keine bessere Wirksamkeit zeigen, werden sie aufgrund ihres günstigeren Nebenwirkungsprofils bei älteren Patienten, einfacherer Aufdosierung und ihres geringeren Interaktionspotenzials häufiger verordnet. Die vorgestellten Therapieempfehlungen leiten sich aus pharmakologischen Überlegungen, klinischer Erfahrung, der zu behandelnden Zielsymptomatik und Art und Intensität von Nebenwirkungen ab.

Abstract

Although affecting 40 % of all patients suffering from Parkinson's disease, depression is often neither diagnosed nor treated. Biological and psychological factors contribute to the pathogenesis of depression. As one of three important factors, depressive disorders influence quality of life. The difficulties of diagnosing depression could be overcome by the use of rating instruments like the Beck Depression Inventory or the Montgomery Asberg Depression Scale. Improving the dopaminergic medication is in most of the cases not sufficient enough, so there is need for the use of an antidepressant. Data on the efficacy and the safety of antidepressive treatment in Parkinson's disease are currently too limited to give evidence-based recommendations. Although newer antidepressants like the selective serotonin reuptake inhibitors and older ones like the tricyclic antidepressants are equally effective, the newer ones are recommended more often because of their more favorable adverse effects in older patients, easier dosing and less interactions. The following recommendations depend on pharmacological considerations, clinical experience, the intended-to-treat symptoms and the kind and intensity of adverse effects.

Literatur

  • 1 Poewe W, Luginger E. Depression in parkinson's disease: Impediments to recognition and treatment options.  Neurology. 1999;  52 S2-6
    PubMedGoogle Scholar
  • 2 Shiba M, Bower J H, Maraganore D M. et al . Anxiety disorders and depressive disorders preceding parkinson's disease: A case-control study.  Mov Disord. 2000;  15 669-677
    CrossrefPubMedGoogle Scholar
  • 3 Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism.  Neurology. 1986;  36 1130-1133
    CrossrefPubMedGoogle Scholar
  • 4 Starkstein S E, Mayberg H S, Leiguarda R. et al . A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with parkinson's disease.  J Neurol Neurosurg Psychiatry. 1992;  55 377-382
    PubMedGoogle Scholar
  • 5 Mayberg H S, Solomon D H. Depression in parkinson's disease: A biochemical and organic viewpoint.  Adv Neurol. 1995;  65 49-60
    PubMedGoogle Scholar
  • 6 Becker T, Becker G, Seufert J. et al . Parkinson's disease and depression: Evidence for an alteration of the basal limbic system detected by transcranial sonography.  J Neurol Neurosurg Psychiatry. 1997;  63 590-596
    PubMedGoogle Scholar
  • 7 Mayeux R, Stern Y, Cote L, Williams J B. Altered serotonin metabolism in depressed patients with parkinson's disease.  Neurology. 1984;  34 642-646
    PubMedGoogle Scholar
  • 8 Mayberg H S, Starkstein S E, Sadzot B. et al . Selective hypometabolism in the inferior frontal lobe in depressed patients with parkinson's disease.  Ann Neurol. 1990;  28 57-64
    CrossrefPubMedGoogle Scholar
  • 9 Menza M A, Palermo B, DiPaola R. et al . Depression and anxiety in parkinson's disease: Possible effect of genetic variation in the serotonin transporter.  J Geriatr Psychiatry Neurol. 1999;  12 49-52
    PubMedGoogle Scholar
  • 10 Mossner R, Henneberg A, Schmitt A. et al . Allelic variation of serotonin transporter expression is associated with depression in parkinson's disease.  Mol Psychiatry. 2001;  6 350-352
    CrossrefPubMedGoogle Scholar
  • 11 Stern Y, Marder K, Tang M X, Mayeux R. Antecedent clinical features associated with dementia in parkinson's disease.  Neurology. 1993;  43 1690-1692
    PubMedGoogle Scholar
  • 12 Brown R G, MacCarthy B, Gotham A M. et al . Depression and disability in parkinson's disease: A follow-up of 132 cases.  Psychol Med. 1988;  18 49-55
    CrossrefPubMedGoogle Scholar
  • 13 APA .Diagnostic and statistical manual of mental disorders. 1994
    Google Scholar
  • 14 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;  23 56-62
    CrossrefPubMedGoogle Scholar
  • 15 Montgomery S A, Asberg M. A new depression scale designed to be sensitive to change.  Br J Psychiatry. 1979;  134 382-389
    CrossrefPubMedGoogle Scholar
  • 16 Leentjens A F, Verhey F R, Lousberg R. et al . The validity of the hamilton and montgomery-asberg depression rating scales as screening and diagnostic tools for depression in parkinson's disease.  Int J Geriatr Psychiatry. 2000;  15 644-649
    CrossrefPubMedGoogle Scholar
  • 17 Beck A TWC, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression.  Arch Gen Psychiatry. 1961;  4 561-571
    CrossrefPubMedGoogle Scholar
  • 18 Zung W. A self-rating depression scale.  Arch Gen Psychiatry. 1965;  12 63-70
    PubMedGoogle Scholar
  • 19 Bech P WL. Applicability and validity of the major depression inventory in patients with parkinson's disease.  Nord J Psychiatry. 1998;  52 305-309
    CrossrefPubMedGoogle Scholar
  • 20 Leentjens A F, Verhey F R, Luijckx G J, Troost J. The validity of the beck depression inventory as a screening and diagnostic instrument for depression in patients with parkinson's disease.  Mov Disord. 2000;  15 1221-1224
    CrossrefPubMedGoogle Scholar
  • 21 Bauer M, Whybrow P C, Angst J. et al . World federation of societies of biological psychiatry (wfsbp) guidelines for biological treatment of unipolar depressive disorders, part 1: Acute and continuation treatment of major depressive disorder.  World J Biol Psychiatry. 2002;  3 5-43
    CrossrefPubMedGoogle Scholar
  • 22 Nierenberg A A, DeCecco L M. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression.  J Clin Psychiatry. 2001;  62, Suppl 16 5-9
    PubMedGoogle Scholar
  • 23 Kirchheiner J, Bertilsson L, Bruus H. et al . Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.  Pharmacopsychiatry. 2003;  36, Suppl 3 S235-243
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Menza M A, Sage J, Marshall E. et al . Mood changes and „on-off” phenomena in parkinson's disease.  Mov Disord. 1990;  5 148-151
    CrossrefPubMedGoogle Scholar
  • 25 Allain H, Schuck S, Mauduit N. Depression in parkinson's disease.  Bmj. 2000;  320 1287-1288
    CrossrefPubMedGoogle Scholar
  • 26 Shaw K MLA, Stern G M. The impact of treatment with levodopa on parkinson's disease.  Q J Med. 1980;  49 283-293
    PubMedGoogle Scholar
  • 27 Rogers D C, Costall B, Domeney A M. et al . Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.  Psychopharmacology (Berl). 2000;  151 91-97
    CrossrefPubMedGoogle Scholar
  • 28 Perugi G, Toni C, Ruffolo G. et al . Adjunctive dopamine agonists in treatment-resistant bipolar ii depression: An open case series.  Pharmacopsychiatry. 2001;  34 137-141
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Ostow M. Pramipexole for depression.  Am J Psychiatry. 2002;  159 320-321
    CrossrefPubMedGoogle Scholar
  • 30 Corrigan M H, Denahan A Q, Wright C E. et al . Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.  Depress Anxiety. 2000;  11 58-65
    CrossrefPubMedGoogle Scholar
  • 31 Lattanzi L, Dell'Osso L, Cassano P. et al . Pramipexole in treatment-resistant depression: A 16-week naturalistic study.  Bipolar Disord. 2002;  4 307-314
    CrossrefPubMedGoogle Scholar
  • 32 Rektorova I, Rektor I, Bares M. et al . Pramipexole and pergolide in the treatment of depression in parkinson's disease: A national multicentre prospective randomized study.  Eur J Neurol. 2003;  10 399-406
    CrossrefPubMedGoogle Scholar
  • 33 Andersen J, Aabro E, Gulmann N. et al . Anti-depressive treatment in parkinson's disease. A controlled trial of the effect of nortriptyline in patients with parkinson's disease treated with l-dopa.  Acta Neurol Scand. 1980;  62 210-219
    CrossrefPubMedGoogle Scholar
  • 34 Wermuth L, Sorensen P S, Timm B. et al . Depression in idiopathic parkinson's disease treated with citalopram - a placebo-controlled trial.  Nordic Journal of Psychiatry. 1998;  52 163-169
    CrossrefPubMedGoogle Scholar
  • 35 Rabey J, Orlov E, Korczyn A D. Comparison of fluvoxamine versus amitriptyline for treatment of depression in parkinson's disease.  Neurology. 1996;  46 A374
    PubMedGoogle Scholar
  • 36 Shabnam G N, Chung T H, Deane K HO. et al .Therapies for depression in parkinson's disease. Cochrane Database Syst Rev 2003, CD003465
    Google Scholar
  • 37 Emre M. What causes mental dysfunction in parkinson's disease?.  Mov Disord. 2003;  18, Suppl 6 S63-71
    CrossrefPubMedGoogle Scholar
  • 38 Bedard M A, Pillon B, Dubois B. et al . Acute and long-term administration of anticholinergics in parkinson's disease: Specific effects on the subcortico-frontal syndrome.  Brain Cogn. 1999;  40 289-313
    PubMedGoogle Scholar
  • 39 Bosboom J L, Stoffers D, Wolters E. The role of acetylcholine and dopamine in dementia and psychosis in parkinson's disease.  J Neural Transm Suppl. 2003;  65 185-195
    PubMedGoogle Scholar
  • 40 Emre M. Dementia in parkinson's disease: Cause and treatment.  Curr Opin Neurol. 2004;  17 399-404
    CrossrefPubMedGoogle Scholar
  • 41 Sternic N, Kacar A, Filipovic S, Svetel M. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase a inhibitor, in parkinson's disease.  Clin Neuropharmacol. 1998;  21 93-96
    PubMedGoogle Scholar
  • 42 Stassen H H, Angst J, Szegedi A. How to assess the onset of antidepressant effect. Empirical data on 2788 patients.  Pharmacopsychiatry. 2003;  36 265
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Thase M E, Rush A J. When at first you don't succeed: Sequential strategies for antidepressant nonresponders.  J Clin Psychiatry. 1997;  58, suppl 13 23-29
    PubMedGoogle Scholar
  • 44 Strang R R. Imipramine in treatment of parkinsonism: A double-blind placebo study.  Br Med J. 1965;  5452 33-34
    PubMedGoogle Scholar
  • 45 Laitinen L. Desipramine in treatment of parkinson's disease. A placebo-controlled study.  Acta Neurol Scand. 1969;  45 109-113
    CrossrefPubMedGoogle Scholar
  • 46 Steur E N. Increase of parkinson disability after fluoxetine medication.  Neurology. 1993;  2 211-213
    PubMedGoogle Scholar
  • 47 Jimenez-Jimenez F J, Tejeiro J, Martinez-Junquera G. et al . Parkinsonism exacerbated by paroxetine.  Neurology. 1994;  44 2406
    PubMedGoogle Scholar
  • 48 Simons A. Fluoxetine in parkinson's disease.  Movement Disorders. 1996;  11 581-582
    CrossrefPubMedGoogle Scholar
  • 49 Linazasoro G. Worsening of parkinson's disease by citalopram.  Parkinson Rel Disord. 2000;  6 111-113
    CrossrefPubMedGoogle Scholar
  • 50 Ceravolo R, Nuti A, Piccinni A. et al . Paroxetine in parkinson's disease: Effects on motor and depressive symptoms.  Neurology. 2000;  55 1216-1218
    PubMedGoogle Scholar
  • 51 Tesei S, Antonini A, Canesi M. et al . Tolerability of paroxetine in parkinson's disease: A prospective study.  Mov Disord. 2000;  15 986-989
    CrossrefPubMedGoogle Scholar
  • 52 Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias.  Neurology. 1999;  53 1154
    PubMedGoogle Scholar
  • 53 Montastruc J L, Fabre N, Blin O. et al . Does fluoxetine aggravate parkinson's disease? A pilot prospective study.  Mov Disord. 1995;  10 355-357
    CrossrefPubMedGoogle Scholar
  • 54 McCance-Katz E F, Marek K L, Price L H. Serotonergic dysfunction in depression associated with parkinson's disease.  Neurology. 1992;  42 1813-1814
    PubMedGoogle Scholar
  • 55 Shulman L MSC, Liefert R. Therapeutic effects of sertraline in patients with parkinson's disease.  Mov Disord. 1996;  1 12
    PubMedGoogle Scholar
  • 56 Hauser RA ZT. Sertraline for the treatment of depression in parkinson's disease.  Mov Disord. 1997;  12 756-759
    CrossrefPubMedGoogle Scholar
  • 57 Lemke M R. Reboxetine treatment of depression in parkinson's disease.  J Clin Psychiatry. 2000;  61 872
    PubMedGoogle Scholar

Prof. Dr. G. Deuschl

Klinik für Neurologie · Universitätsklinikum Schleswig-Holstein · Campus Kiel

Schittenhelmstraße 10

24105 Kiel

Email: g.deuschl@neurologie.uni-kiel.de